As supply chain vulnerabilities intensify and competition accelerates, the cost of this underutilization could risk India's competitive position.

Multiply Labs' goal is to enable scalable, high-throughput manufacturing while maintaining rigorous quality and regulatory standards.

To evaluate the potential for applying GMP-ready robotic systems to commercial-scale cell therapy manufacturing.

SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) -- The transaction is subject to customary closing ...

A living evidence approach treats evidence as shared infrastructure rather than as a series of isolated projects.

Jan 30 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.

By Maggie Fick and Michael Erman SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most challenging aspect of drug development -- finding new molecules that lead to ...

The new DeltaV MES Recipe Importer Tool automates batch record creation for workflow execution, reducing timelines from ...

The companies will invest up to $1 billion over five years to support discovery and development powered by artificial ...

Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your inbox, and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...